Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10234 vs TDF in Chronic Hepatitis B
NCT03903796Phase 3Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir amibufenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Proportion of Patients with HBV DNA < 20 IU/mL at 48 weeks. Started Aug 2018; status: completed.
02
Drugs
tenofovir amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03903796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903796.